Singapore, April 20 -- China-based Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, has announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures.

Separately, Medtronic and Pulnovo have entered into a commercial agreement that contemplates potential future commercialisation opportunities. 

This financing strengthens Pulnovo's strategic collaboration with global industry and capital p...